RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)
Clinical trials for RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) explained in plain language.
Never miss a new study
Get alerted when new RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) trials appear
Sign up with your email to follow new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New MS drug copy aims to match blockbuster treatment
Disease control Recruiting nowThis study is testing if a new drug called ABP 692 works the same way as the established MS treatment Ocrevus. It will involve 444 people with relapsing-remitting MS to see if the drugs have similar levels in the body and are equally effective at reducing new brain lesions seen o…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New MS drug enters final testing phase to control disease activity
Disease control Recruiting nowThis study is testing whether a new drug called BCD-281 works as well as an existing reference drug for people with relapsing-remitting multiple sclerosis (RRMS). About 292 participants will be randomly assigned to receive either BCD-281 or the reference drug for 72 weeks, follow…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Could a gut bacteria supplement stop MS in its tracks?
Disease control Recruiting nowThis study is testing whether a supplement called indole-3-propionic acid (IPA), a natural substance made by gut bacteria, can help control multiple sclerosis. Researchers will give the supplement to 220 adults with relapsing-remitting MS to see if it reduces flare-ups, prevents …
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: NA • Sponsor: Glostrup University Hospital, Copenhagen • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Eyes could reveal hidden clues about MS treatment success
Knowledge-focused Recruiting nowThis study is testing a new eye-tracking tool to see if it can detect subtle changes in eye movements that might indicate how well a multiple sclerosis (MS) treatment is working. It will involve 224 Canadian adults with active relapsing-remitting MS who are already prescribed the…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC